---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-028748"
form_type: "8-K"
ticker: "MNKD"
cik: "0000899460"
company_name: "MANNKIND CORP"
filed_at: "2022-08-09T23:59:59+00:00"
generated_at: "2026-06-24T02:29:49.696231+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# MannKind Q2 2022 revenue $18.9M, net loss narrows to $29.0M; Tyvaso DPI approved

## Summary
- Commercial product net revenue $12.7M (Afrezza $10.6M, V-Go $2.1M), up 28% YoY; collaboration $5.9M.
- Net loss $29.0M ($0.11/sh) vs $35.5M ($0.14/sh) in Q2 2021; narrowed due to prior-year debt extinguishment loss.
- Tyvaso DPI (pulmonary hypertension) FDA approved May 2022; first manufacturing & royalty revenue from United Therapeutics recognized in Q2.
- V-Go insulin patch acquisition May 31 generated $2.1M net revenue in June; gross profit $0.8M.
- Afrezza gross margin improved to 68% from 56% on higher sales and lower COGS.

## SEC filing metadata
- accession: 0001564590-22-028748
- form_type: 8-K
- ticker: MNKD
- cik: 0000899460
- company_name: MANNKIND CORP
- filed_at: 2022-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/899460/000156459022028748/0001564590-22-028748-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/899460/000156459022028748/mnkd-8k_20220809.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-028748
- JSON: https://secwatch.observer/filing/0001564590-22-028748.json
- Plain text: https://secwatch.observer/filing/0001564590-22-028748.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.